000079111 001__ 79111 000079111 005__ 20190709135426.0 000079111 0247_ $$2doi$$a10.1080/17425247.2016.1205585 000079111 0248_ $$2sideral$$a97524 000079111 037__ $$aART-2017-97524 000079111 041__ $$aeng 000079111 100__ $$aLuque-Michel, Edurne 000079111 245__ $$aClinical advances of nanocarrier-based cancer therapy and diagnostics 000079111 260__ $$c2017 000079111 5060_ $$aAccess copy available to the general public$$fUnrestricted 000079111 5203_ $$aIntroduction: Cancer is a leading cause of death worldwide and efficient new strategies are urgently needed to combat its high mortality and morbidity statistics. Fortunately, over the years, nanotechnology has evolved as a frontrunner in the areas of imaging, diagnostics and therapy, giving the possibility of monitoring, evaluating and individualizing cancer treatments in real-time. Areas covered: Polymer-based nanocarriers have been extensively studied to maximize cancer treatment efficacy and minimize the adverse effects of standard therapeutics. Regarding diagnosis, nanomaterials like quantum dots, iron oxide nanoparticles or gold nanoparticles have been developed to provide rapid, sensitive detection of cancer and, therefore, facilitate early treatment and monitoring of the disease. Therefore, multifunctional nanosystems with both imaging and therapy functionalities bring us a step closer to delivering precision/personalized medicine in the cancer setting. Expert opinion: There are multiple barriers for these new nanosystems to enter the clinic, but it is expected that in the near future, nanocarriers, together with new ‘targeted drugs’, could replace our current treatments and cancer could become a nonfatal disease with good recovery rates. Joint efforts between scientists, clinicians, the pharmaceutical industry and legislative bodies are needed to bring to fruition the application of nanosystems in the clinical management of cancer. 000079111 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/ 000079111 590__ $$a5.553$$b2017 000079111 591__ $$aPHARMACOLOGY & PHARMACY$$b18 / 261 = 0.069$$c2017$$dQ1$$eT1 000079111 592__ $$a1.432$$b2017 000079111 593__ $$aPharmaceutical Science$$c2017$$dQ1 000079111 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion 000079111 700__ $$aImbuluzqueta, Edurne 000079111 700__ $$0(orcid)0000-0002-6873-5244$$aSebastián, Víctor$$uUniversidad de Zaragoza 000079111 700__ $$aBlanco-Prieto, María J. 000079111 7102_ $$15005$$2555$$aUniversidad de Zaragoza$$bDpto. Ing.Quím.Tecnol.Med.Amb.$$cÁrea Ingeniería Química 000079111 773__ $$g14, 1 (2017), 75-92$$pExpert Opinion on Drug Delivery$$tExpert Opinion on Drug Delivery$$x1742-5247 000079111 8564_ $$s2122836$$uhttps://zaguan.unizar.es/record/79111/files/texto_completo.pdf$$yPostprint 000079111 8564_ $$s12846$$uhttps://zaguan.unizar.es/record/79111/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint 000079111 909CO $$ooai:zaguan.unizar.es:79111$$particulos$$pdriver 000079111 951__ $$a2019-07-09-11:29:12 000079111 980__ $$aARTICLE